Prof. Dr. Nicolas Mach, on behalf of Philogen, is presenting a poster about the Phase I DODEKA study on October 23rd, entitled “Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors”
Prof. Dr. Lukas Flatz, on behalf of Philogen, is presenting a poster about the Phase II Duncan Study on October 22nd, entitled “Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity”.